Wells Fargo upgrades CareDx to Equal Weight
In a report released today, Yi Chen from H.C. Wainwright reiterated a Hold rating on CareDx (CDNA – Research Report), with a price target of ...
CareDx (NASDAQ:CDNA) expects to incur a loss (GAAP) of around $32M to $34M for the fourth quarter of 2024, on revenue of $85M ...
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...
CareDx CDNA has been analyzed by 3 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below ...
CareDx faces regulatory challenges and lacks a durable competitive advantage in a fragmented and competitive market, with no clear moat to protect its position, leading to a poor risk-reward profile ...
The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024.
Continuing our mission to serve transplant patients, we achieved our sixth consecutive quarter of testing services volume growth in the fourth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback